Article Text

PDF
FRI0426 Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.
  1. E. L. Kneepkens1,
  2. J. C. Wei2,
  3. M. T. Nurmohamed1,3,
  4. C. Y. Chen2,
  5. K. J. Yeo2,
  6. I. E. van der Horst-Bruinsma1,3,
  7. G. J. Wolbink1,4,
  8. C. L. Krieckaert1
  1. 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
  2. 2Chung Shan Medical University Hospital, Taichung, Taiwan, Province of China
  3. 3Rheumatology, VU University medical centre
  4. 4Sanquin Research, Amsterdam, Netherlands

Abstract

Background Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases.

Objectives To study the relation between clinical response, adalimumab levels and anti-drug antibodies (ADA) in ankylosing spondylitis (AS) patients.

Methods Observational cohort study of 115 consecutive AS patients treated with adalimumab in the Netherlands (n=85) and Taiwan (n=30), monitored during a maximum of 24 weeks of follow-up. Adalimumab levels and ADA titres were determined using an enzyme linked immunosorbent assay (ELISA) and an Antigen Binding Test (ABT), respectively, designed by Sanquin Research, Amsterdam. Response to adalimumab treatment was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response (50% improvement or an absolute improvement of 2 points on a BASDAI, scale 0-10) and disease activity was measured using the AS Disease Activity Score, including CRP (ASDAS).

Results Of 115 patients 78 (67.8%) were male and 95 (82.6%) were HLA-B27 positive. At baseline median BASDAI (IQR) was 6.4 (4.5-7.6) and mean ASDAS (SD) was 3.5 (1.0). After 24 weeks 49 (42.6%) patients were BASDAI responders (last observation carried forward), mean ASDAS (SD) for responders was 1.5 (1.0) vs. 2.6 (1.0) for non-responders (p<0.001). Nine patients dropped out: 8 patients (7.0%) due to treatment failure or adverse events and 1 due to loss of follow-up. Thirty-one (27.0%) patients had detectable ADA. After 24 weeks median adalimumab levels (mg/L) (IQR) were significantly higher for ADA negative patients than for ADA positive patients (12,7 (8.2-18.0) vs. 1.2 (0.0-2.0), p<0.001). General estimate equation analysis demonstrated a significant association between adalimumab levels and ASDAS (p=0.02; RC -1.1; 95% CI -2.0 to -0.2). For BASDAI response no significant association with adalimumab levels was found. Eleven (9.6%) patients had no detectable adalimumab levels and high detectable ADA titres (>100 AU/mL). In these patients CRP remained elevated.

Conclusions Adalimumab levels are related to clinical response in AS patients and are influenced by ADA detectable with an ABT. Therefore therapeutic drug monitoring should be investigated further as a possible tool to optimise treatment.

Disclosure of Interest E. Kneepkens: None Declared, J. Wei: None Declared, M. Nurmohamed Grant/research support from: Abbott, Roche, Pfizer, Consultant for: Abbott, Roche, Pfizer, MSD, UCB, SOBI and BMS, Speakers bureau: Abbott, Roche, Pfizer, C. Chen: None Declared, K. Yeo: None Declared, I. van der Horst-Bruinsma: None Declared, G. Wolbink Grant/research support from: Pfizer, Speakers bureau: Pfizer, Amgen, C. Krieckaert: None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.